Evidence
We share observational data and intellectual property developed during product and digital therapeutic development, to the extent publicly disclosable.
Clinical Evidence Whitepaper
This public whitepaper summarizes cranial measurements collected during AiBrain use, including the study design, key observations, interpretation, and use-related findings.
Approximately 47% relative decrease observed
CVAI shows the degree of left-right head-shape asymmetry. A lower value means less asymmetry.
CVAI, the asymmetry measure, decreased while the cranial index (CI) did not change significantly (p=0.14).
The number of infants with both baseline and final measurements.
The average time between the first and final measurements.
The final CVAI value was lower in 22 of 23 infants.
These are before-and-after changes observed in a single-arm evaluation without a control group. Natural history cannot be separated from the influence of product use.
Intellectual Property
AiBrio has translated problems identified in clinical practice into technology and product form.
Patent applications covering infant torticollis and posture-recognition data.
Patent applications related to respiratory rehabilitation.
Patent applications for the AiBrain mattress and related everyday products.
Patent titles are descriptive translations of the original Korean filings.
